Symptomatic Necrosis With Antibody-Drug Conjugates and Concurrent Stereotactic Radiotherapy for Brain Metastases

Emily S Lebow; Luke R G Pike; Andrew D Seidman; Nelson Moss; Kathryn Beal; Yao Yu

doi:10.1001/jamaoncol.2023.4492

Symptomatic Necrosis With Antibody-Drug Conjugates and Concurrent Stereotactic Radiotherapy for Brain Metastases

JAMA Oncol. 2023 Dec 1;9(12):1729-1733. doi: 10.1001/jamaoncol.2023.4492.

Authors

Emily S Lebow^{1

2}, Luke R G Pike¹, Andrew D Seidman³, Nelson Moss⁴, Kathryn Beal⁵, Yao Yu¹

Affiliations

¹ Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
² Department of Radiation Oncology, University of Pennsylvania, Philadelphia.
³ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
⁴ Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, News York, New York.
⁵ Department of Radiation Oncology, Weill Cornell Medical Center, New York, New York.

No abstract available

Plain language summary

This cohort study investigates whether brain metastases that manifest after stereotactic radiotherapy with concurrent antibody-drug conjugates are associated with an increased risk of symptomatic radiation necrosis.

MeSH terms

Brain / pathology
Brain Neoplasms* / secondary
Humans
Immunoconjugates*
Necrosis / pathology
Radiosurgery* / adverse effects
Retrospective Studies

Substances

Immunoconjugates

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States